<DOC>
	<DOC>NCT02844153</DOC>
	<brief_summary>Metformin is the most widely prescribed oral treatment for diabetes, and the only one that showed a survival benefit. Yet, there is no consensus on the optimal dose and withdrawal of metformin in chronic kidney disease (CKD) patients. The aim of the study is to describe the use and side-effects of metformin in CKD patients in routine practice.</brief_summary>
	<brief_title>Metformin Use in Chronic Kidney Disease: The CKD-Met Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>18 years old or more Type 2 diabetes Seen by a nephrologist (consultation or hospitalization) between March 2014 and March 2020 in the Department of Nephrology, Lyon Sud university hospital, France Ongoing treatment by dialysis Kidney transplantation Type 1 diabetes Missing data (metformin treatment)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Metformin</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>antidiabetic medications</keyword>
	<keyword>lactic acidosis</keyword>
</DOC>